ADIAL PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.26 USD | -13.41% |
|
+97.50% | +19.99% |
| Apr. 12 | Top Premarket Decliners | MT |
| Apr. 10 | Top Midday Gainers | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 10.58M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M | Net income 2025 * | -9M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.31
x | P/E ratio 2025 * |
-1.64
x | Employees | 6 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.98% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +12.02% | ||
| 1 week | +130.97% | ||
| Current month | +96.24% | ||
| 1 month | +65.19% | ||
| 3 months | +79.85% | ||
| 6 months | -5.78% | ||
| Current year | +40.32% |
1 week
1.75
3.10
1 month
1.053.10
Current year
0.774.17
1 year
0.7714.00
3 years
0.77127.00
5 years
0.77127.00
10 years
0.77236.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bankole Johnson
FOU | Founder | 64 | 10-10-31 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Joseph Truluck
DFI | Director of Finance/CFO | 46 | 16-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jack W. Reich
LAW | General Counsel | - | 20-05-18 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Tony Goodman
COO | Chief Operating Officer | 60 | 17-06-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 2.259 | -13.44% | 584 937 |
| 24-04-15 | 2.61 | +12.02% | 3,281,378 |
| 24-04-12 | 2.33 | -21.81% | 2,752,082 |
| 24-04-11 | 2.98 | +27.90% | 37,666,761 |
| 24-04-10 | 2.33 | +106.19% | 106,739,891 |
Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT
More quotes
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Companyâs drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is used for the treatment of AUD in subjects with certain target genotypes, which were identified using its companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for the treatment of AUD. The Companyâs AD04 also has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.61
USD
Average target price
7.5
USD
Spread / Average Target
+187.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.32% | 9.45M | |
| -2.34% | 102B | |
| +2.31% | 97.22B | |
| +4.22% | 22.27B | |
| -16.72% | 20.84B | |
| -4.50% | 19.19B | |
| -41.75% | 16.76B | |
| -23.26% | 14.76B | |
| -0.02% | 13.54B | |
| +22.69% | 11.53B |
- Stock Market
- Equities
- ADIL Stock
